<DOC>
	<DOCNO>NCT00006466</DOCNO>
	<brief_summary>RATIONALE : Biological therapy beta alethine use different way stimulate immune system stop cancer cell grow . PURPOSE : Phase I/II trial study effectiveness beta alethine treat patient myeloma .</brief_summary>
	<brief_title>Beta Alethine Treating Patients With Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Determine antitumor effect low-dose beta alethine patient myeloma progressive monoclonal gammopathy undetermined significance . - Determine effect regimen anemia , performance status , pain , delayed-type hypersensitivity ( immune response ) patient . - Determine safety regimen patient . OUTLINE : This multicenter study . Patients receive beta alethine subcutaneously every 2 week 6 dos . At day 85 , patient may receive additional 12-week course therapy absence disease progression unacceptable toxicity . Patients apparent complete response receive additional course . Patients follow 2 week . PROJECTED ACCRUAL : A total 13-37 patient accrue study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Cysteamine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven myeloma Multiple myeloma Indolent myeloma slowly progressive bone pathology Smoldering myeloma bone pathology progressive increase Mprotein Solitary myeloma OR Diagnosis evolve monoclonal gammopathy undetermined significance increase Mprotein decrease hemoglobin level Measurable Mprotein Bence Jones protein Indolent disease require therapy allow No clinical sign evidence active brain involvement leptomeningeal disease PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 50100 % Life expectancy : At least 4 month Hematopoietic : See Disease Characteristics Neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic : Bilirubin le 2.0 mg/dL Transaminases great 2.5 time upper limit normal Renal : Creatinine great 2.0 mg/dL Creatinine clearance least 60 mL/min Cardiovascular : No acute change electrocardiogram No uncontrolled angina , heart failure , arrhythmia Other : Adequate nutritional status ( total protein least 60.0 g/L , albumin least 35 g/L ) HIV negative No AIDS No active bacterial infection ( e.g. , abscess ) fistula No history alcoholism , drug addiction , psychotic disorder would preclude study No nonmalignant disease would preclude study Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy cytokine Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas , mitomycin , highdose carboplatin ) Endocrine therapy : No concurrent corticosteroid Radiotherapy : No prior radiotherapy great 25 % bone marrow Surgery : Recovered prior surgery No prior solid organ transplantation Other : No concurrent investigational agent No concurrent immunosuppressive agent No concurrent antiinflammatory agent , include aspirin overthecounter prescription nonsteroidal antiinflammatory drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2002</verification_date>
	<keyword>monoclonal gammopathy undetermined significance</keyword>
	<keyword>isolated plasmacytoma bone</keyword>
	<keyword>extramedullary plasmacytoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>